How to buy Nektar Therapeutics stock (NKTR)

Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.93 – a decrease of 8.09% over the previous week. Nektar Therapeutics employs 137 staff and has a trailing 12-month revenue of around $93.1 million.

Our top picks for where to buy Nektar Therapeutics stock

Buy Nektar Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Nektar Therapeutics stock price (NASDAQ: NKTR)

Use our graph to track the performance of NKTR stocks over time.

Nektar Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.93
52-week range	$0.47 - $1.93
50-day moving average more info button	$1.21
200-day moving average more info button	$1.26
Wall St. target price	$4.70
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.84

Is it a good time to buy Nektar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nektar Therapeutics price performance over time

Historical closes compared with the close of $0.941 from 2024-12-19

1 week (2024-12-13)	-6.83%
1 month (2024-11-22)	-10.38%
3 months (2024-09-20)	-27.62%
6 months (2024-06-21)	-18.88%

1 year (2023-12-21)	99.36%
2 years (2022-12-21)	-62.06%
3 years (2021-12-21)	15.37
5 years (2019-12-20)	21.32

Is Nektar Therapeutics stock undervalued or overvalued?

Valuing Nektar Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nektar Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Nektar Therapeutics's PEG ratio

Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Nektar Therapeutics financials

Revenue TTM	$93.1 million
Gross profit TTM	$70.4 million
Return on assets TTM	-22.64%
Return on equity TTM	-161.63%
Profit margin	-180.7%
Book value	$0.27
Market Capitalization more info button	$170.6 million

TTM: trailing 12 months

Nektar Therapeutics share dividends

We're not expecting Nektar Therapeutics to pay a dividend over the next 12 months.

Have Nektar Therapeutics's shares ever split?

Nektar Therapeutics's shares were split on a 2:1 basis on 22 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Nektar Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Nektar Therapeutics shares which in turn could have impacted Nektar Therapeutics's share price.

Nektar Therapeutics share price volatility

Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $0.47 up to $1.928. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 0.61. This would suggest that Nektar Therapeutics's shares are less volatile than average (for this exchange).

Nektar Therapeutics overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd. ; AstraZeneca AB; UCB Pharma S. A. ; F.

Frequently asked questions

What percentage of Nektar Therapeutics is owned by insiders or institutions?
Currently 1.039% of Nektar Therapeutics shares are held by insiders and 76.622% by institutions. How many people work for Nektar Therapeutics?
Latest data suggests 137 work at Nektar Therapeutics. When does the fiscal year end for Nektar Therapeutics?
Nektar Therapeutics's fiscal year ends in December. Where is Nektar Therapeutics based?
Nektar Therapeutics's address is: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 What is Nektar Therapeutics's ISIN number?
Nektar Therapeutics's international securities identification number is: US6402681083 What is Nektar Therapeutics's CUSIP number?
Nektar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 457191104